Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Sells $144,192.30 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 8,078 shares of the business’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $17.85, for a total transaction of $144,192.30. Following the completion of the sale, the chief financial officer now owns 217,293 shares of the company’s stock, valued at $3,878,680.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Day One Biopharmaceuticals Stock Down 2.3 %

Day One Biopharmaceuticals stock opened at $17.17 on Monday. The business has a 50 day moving average price of $15.45 and a two-hundred day moving average price of $14.07. Day One Biopharmaceuticals, Inc. has a 12 month low of $9.67 and a 12 month high of $18.07. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -7.21 and a beta of -1.44.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). On average, analysts expect that Day One Biopharmaceuticals, Inc. will post -2.67 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on DAWN. Needham & Company LLC boosted their target price on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Piper Sandler restated an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, April 24th. The Goldman Sachs Group cut their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a report on Tuesday, February 27th. Finally, Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $39.33.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of hedge funds have recently made changes to their positions in DAWN. Arizona State Retirement System boosted its position in shares of Day One Biopharmaceuticals by 8.8% during the 3rd quarter. Arizona State Retirement System now owns 12,363 shares of the company’s stock valued at $152,000 after acquiring an additional 995 shares in the last quarter. Quintet Private Bank Europe S.A. lifted its stake in Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Day One Biopharmaceuticals by 130.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after purchasing an additional 1,262 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in shares of Day One Biopharmaceuticals by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after purchasing an additional 1,445 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in shares of Day One Biopharmaceuticals by 9.7% in the 3rd quarter. Principal Financial Group Inc. now owns 17,781 shares of the company’s stock worth $218,000 after buying an additional 1,569 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.